Nephrology
Nephrology is a specialized branch of medicine that focuses on the study and treatment of kidney-related conditions. It encompasses the understanding of normal kidney function, known as renal physiology, as well as the pathophysiology of kidney diseases. This specialty is crucial for both adult internal medicine and pediatric medicine, addressing the preservation of kidney health and the management of kidney diseases through various means, including dietary modifications, medication, and renal replacement therapy.[2.1] The term "nephrology" is derived from the Greek word 'nephros,' which translates to 'kidney,' and is pronounced as ne-FROL-uh-jee.[3.1] Nephrologists are the medical professionals who specialize in this field, providing comprehensive care and education to patients regarding their kidney health.[1.1]
Nephrology plays a crucial role in healthcare, particularly due to the rising prevalence of kidney diseases globally, which are often linked to increasing rates of diabetes and hypertension. The demand for nephrologists is significant as they are essential in managing these complex conditions and improving patient outcomes.[4.1]
Chronic kidney disease (CKD) is a major public health concern, with an estimated 35.5 million adults in the United States affected, many of whom are unaware of their condition. Symptoms of kidney disease often do not manifest until the disease has progressed to severe stages, making early detection and management critical.[24.1] The classification of CKD into five stages reflects the severity of the disease, with most individuals remaining asymptomatic until they approach end-stage renal disease (ESRD).[23.1]
Kidney health is significantly influenced by socioeconomic factors, which affect both the prevalence and outcomes of kidney diseases. Healthy People 2020, the US national blueprint for public health goals, explicitly aims to eliminate health disparities related to socioeconomic status among patients with kidney disease by 2020. This initiative includes a focus on reducing disparities in the occurrence and outcomes of chronic kidney disease (CKD), which are well-recognized issues in public health.[7.1] Furthermore, addressing the needs of patients with chronic kidney disease requires a commitment to data, education, and community engagement, particularly for those impacted by social determinants of health (SDOH).[27.1]
Community education and awareness campaigns are essential for preventing kidney diseases and promoting early detection. Effective strategies include leveraging technology and social media to reach at-risk populations, enhancing support networks, and providing education on lifestyle changes that can mitigate risk factors associated with CKD.[28.1] The International Society of Nephrology (ISN) has also launched campaigns to raise awareness about CKD and its risk factors, promoting early detection through accessible resources.[30.1]
The study of kidney function has evolved significantly over the centuries, beginning with early anatomical observations and culminating in more detailed physiological insights. Bartolomeo Eustachio (1514-1574) initiated the structural study of kidney function, while Jean Fernel (1497-1558) contributed to the understanding of its physiology and pathology. Joan Baptista Van Helmont (1577-1644) further advanced the field by chemically analyzing urine and identifying calculi as a principal cause of kidney disease during that era.[47.1]
In the 17th century, Lorenzo Bellini made a groundbreaking contribution with his work "Anatomical Exercise on the Structure and Function of the Kidney," published in 1662. In this seminal text, Bellini revealed that the kidney is composed of numerous tiny canals, a discovery that significantly enhanced the understanding of renal anatomy.[63.1] This revelation led to the generation of new information regarding renal structure, function, and urine composition, both in health and disease, and established a foundation for future research in nephrology.[64.1]
Prior to Bellini, Galen's studies of the kidneys represented a pivotal moment in medical history, bridging ancient practices with early anatomical understanding. His meticulous observations provided insights into renal function and pathology, influencing medical thought for centuries. Galen was among the first to accurately describe kidney function and the process of micturition, coining the term "ureter" and recognizing the importance of a competent ureterovesical junction.[66.1] These early contributions laid the groundwork for subsequent advancements in nephrology, shaping the trajectory of kidney research and understanding.
The development of nephrology as a specialty has its roots in significant historical milestones that have shaped the understanding and treatment of kidney diseases. One of the earliest contributions to nephrology was made by Galen, who recognized the urine-producing function of the kidneys, laying the groundwork for future anatomical studies of renal function.[43.1] The invention of the microscope further advanced the field, allowing for detailed examination of renal structures, with notable contributions from scientists like Bellini, who demonstrated the canalicular organization of the renal parenchyma.[43.1]
In the 20th century, nephrology emerged as a distinct medical specialty, particularly in the latter half, due to groundbreaking advancements such as renal biopsy, dialysis, and kidney transplantation.[46.1] These developments transformed the diagnostic and therapeutic landscape of kidney diseases. Renal biopsy, in particular, shifted the diagnostic approach from a purely clinical methodology to one grounded in morphological analysis, significantly enhancing the accuracy of diagnoses.[46.1]
The establishment of clinical practice guidelines by the U.S. National Kidney Foundation in 2002 marked another pivotal moment in nephrology, providing a standardized definition of chronic kidney disease (CKD) and introducing a classification system based on the severity of kidney function.[44.1] This framework has been instrumental in guiding clinical practice and improving patient outcomes.
The Renaissance period also played a crucial role in the scientific study of nephrology, as it marked the beginning of a more systematic approach to understanding kidney function.[48.1] The intellectual movement of this era fostered advancements that have continued to evolve over the centuries, culminating in the sophisticated techniques and methodologies employed in modern nephrology.
Chronic kidney disease (CKD) is the most common type of kidney disease, characterized by a gradual decline in kidney function over time.[83.1] The kidneys, which are two bean-shaped organs about the size of a fist, play a crucial role in filtering extra water and waste products from the blood to produce urine.[84.1] When the kidneys are damaged, as seen in CKD, they cannot filter blood effectively, leading to a buildup of waste in the body.[84.1] Individuals with diabetes or high blood pressure are at greater risk for developing kidney disease, including CKD.[84.1] Understanding these risk factors is essential for recognizing the potential for kidney damage and the importance of early intervention.[83.1]
Several risk factors contribute to the development and progression of CKD, with diabetes mellitus (DMT2) and hypertension being among the most significant. Both conditions are chronic and can lead to further organ damage, exacerbating the effects of CKD.[86.1] The interplay between diabetes and CKD is complex, necessitating consistent monitoring and a multidisciplinary approach to manage the health of affected individuals effectively.[88.1] Furthermore, glycemic control is crucial in the early stages of CKD, as poor management can accelerate renal failure.[89.1]
Dietary modifications are essential for managing Chronic Kidney Disease (CKD) at various stages. In the early stages, specifically Stage 1 and Stage 2 CKD, dietary changes aim to preserve kidney function, reduce blood pressure, and control blood glucose levels, as kidneys still function well during these stages.[93.1] It is crucial for individuals to work with a registered dietitian to develop a meal plan that includes enjoyable foods while maintaining kidney health.[90.1] As kidney function declines, particularly in later stages, adjustments in dietary intake become necessary, especially concerning phosphorus and potassium levels, to prevent further complications.[90.1] Healthcare professionals can assist in determining appropriate sodium intake based on the individual's stage of kidney disease and health status, and they advise avoiding salt substitutes that contain potassium, as CKD makes it difficult for the body to eliminate potassium from the blood.[91.1]
Nephrologists are medical doctors who specialize in diagnosing and treating kidney disorders. Their training includes extensive education in internal medicine followed by specialized training in nephrology.[123.1] These experts manage a wide array of kidney-related conditions, such as chronic kidney disease (CKD), kidney failure, and hypertension.[125.1] Additionally, nephrologists play a crucial role in the care of patients requiring dialysis and kidney transplants, as well as in the pre- and post-operative management of these patients.[125.1] Their expertise is essential not only in treating existing kidney conditions but also in preventing the progression of kidney disease, thereby potentially reducing the need for more invasive interventions.[125.1]
In their role as primary care providers, nephrologists not only focus on kidney health but also offer general health care counseling, preventive care, immunizations, and management of minor acute illnesses unrelated to kidney failure.[122.1] They are integral to the care of patients with systemic diseases and comorbidities that affect kidney function, providing care across various settings such as clinics, inpatient units, and dialysis facilities.[126.1]
Nephrologists also play a crucial role in the management of patients undergoing kidney transplantation, addressing the complex medical needs associated with this life-changing procedure.[131.1] Their responsibilities extend to pre-operative and post-operative care, ensuring that patients receive comprehensive support throughout the transplantation process.[125.1]
Nephrologists play a vital role in advocating for public health initiatives that aim to raise awareness about kidney health and address the prevention of kidney disease at the community level. These initiatives are essential for educating the public about the risk factors associated with kidney disease and promoting early detection.[150.1] Advocacy and public policy efforts are conducted both externally and internally within the House of Medicine, significantly influencing the future of kidney care and nephrology practice.[149.1] As the COVID-19 pandemic wanes, there is an urgent need to improve kidney health literacy and early detection of chronic kidney disease (CKD) to compensate for shortages in the nephrology workforce.[152.1] Community health screening programs can be effective for the detection and prevention of kidney diseases; however, significant structural barriers can limit the effectiveness of these programs.[152.1] Furthermore, effective management of advanced CKD involves addressing co-morbidities such as uremia and cardiovascular disease, which are critical for avoiding or delaying dialysis or kidney transplantation.[151.1] The Advancing American Kidney Health Initiative has established goals to enhance efforts in preventing, detecting, and managing kidney disease, particularly by addressing traditional risk factors like diabetes and hypertension.[151.1]
Recent advancements in nephrology have led to significant innovations in the treatment of kidney diseases, particularly diabetic kidney disease (DKD) and chronic kidney disease (CKD). In 2023, research has continued to progress despite previous disruptions caused by the COVID-19 pandemic, with notable developments in clinical trials and new therapeutic agents.[165.1]
One of the most promising advancements is the introduction of the non-steroidal mineralocorticoid receptor antagonist finerenone, which has demonstrated efficacy in reducing kidney and cardiovascular outcomes in patients with type 2 diabetes and CKD.[181.1] The FIDELIO-DKD trial, a phase 3 randomized study, highlighted finerenone's ability to significantly lower the risk of kidney failure and disease progression.[182.1] Furthermore, the integration of finerenone into treatment guidelines for DKD reflects its growing importance in clinical practice, although its high cost and the need for insurance preauthorization present challenges for widespread adoption.[183.1]
In addition to finerenone, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective treatments that not only lower blood sugar levels but also reduce blood pressure and albuminuria, making them particularly beneficial for patients with kidney disease and coronary artery disease.[185.1] A pooled analysis of trials involving finerenone and GLP-1RAs suggests that their combined use may enhance treatment outcomes across diverse patient populations with CKD and type 2 diabetes.[184.1]
Recent clinical trials have highlighted the potential of new therapies such as sparsentan and budesonide in the treatment of proteinuric IgA nephropathy. Specifically, the PROTECT study demonstrated that once-daily treatment with sparsentan resulted in a significant reduction in proteinuria and preservation of kidney function, with a safety profile comparable to that of irbesartan.[169.1] Both sparsentan and budesonide trials utilized the accelerated approval pathway based on proteinuria reduction as a surrogate endpoint, and ongoing phases of these trials will assess their effectiveness in reducing hard endpoints of kidney disease.[170.1] Future analyses, following the completion of the two-year double-blind period, will determine whether the beneficial effects observed with sparsentan translate into long-term nephroprotective potential.[171.1]
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes management, have also gained recognition for their nephroprotective effects, significantly reducing the risk of kidney failure and related complications.[177.1] Their mechanisms, including reduced kidney oxygen consumption and decreased intraglomerular pressure, differentiate them from traditional therapies.[178.1]
As the field of nephrology advances, the integration of innovative therapies, such as virtual clinics for chronic kidney disease (CKD) patients, is gaining traction. These virtual clinics can facilitate remote monitoring and management, potentially reducing the need for emergency dialysis and improving long-term patient outcomes.[187.1] However, the incorporation of such technologies into routine clinical practice is still in its early stages, indicating that further research and development are necessary.[187.1] Additionally, the interdisciplinary nature of genomic research in nephrology is expected to lead to the creation of comprehensive, evidence-based guidelines for integrating genomic information into clinical practice.[186.1] Engaging patients and their families in genetic research can also provide valuable insights into the genetic factors influencing kidney disease, which is crucial for enhancing patient care.[186.1] Despite these promising developments, challenges such as the need for comprehensive guidelines and the complexities of insurance coverage remain significant considerations for the future of kidney disease management.
Recent advancements in nephrology have underscored the significant role of telemedicine, which offers various advantages in patient care. Telemedicine facilitates home therapy, reduces patient travel time and costs, and empowers patients by engaging them in self-care, which collectively enhances patient satisfaction and adherence to treatment protocols.[174.1] Clinical studies have indicated that telemedicine can improve patient satisfaction and treatment outcomes by increasing adherence and the frequency of visits, thereby positively impacting patient care.[172.1] Furthermore, the Centers for Medicare & Medicaid Services expanded telemedicine coverage on March 6, 2020, to include both inpatient and outpatient consultations as well as in-center hemodialysis, which has led to a rapid adoption of telemedicine in nephrology training programs.[173.1] This swift integration of telemedicine has allowed for more comprehensive care, effectively addressing the needs of patients in both outpatient and inpatient settings.
Personalized medicine in nephrology has advanced significantly with the introduction of SGLT2 inhibitors, which confer renal protection through mechanisms such as tubuloglomerular feedback. This mechanism involves SGLT2 inhibitors causing increased sodium delivery along the nephron, which is sensed by macula densa cells. These cells then signal via adenosine to constrict afferent glomerular arterioles, thereby reducing intraglomerular pressure and protecting the glomeruli.[179.1] Notably, similar kidney benefits have been observed in nondiabetic patients with chronic kidney disease (CKD), prompting extensive research into the mechanisms by which SGLT2 inhibitors provide kidney protection.[180.1] Furthermore, the glucose-lowering efficacy and safety of SGLT2 inhibitors are almost comparable in patients with mild CKD to those with normal kidney function. However, in patients with moderate CKD, the efficacy tends to be dampened, and safety concerns may arise. The use of SGLT2 inhibitors is contraindicated in patients with severe CKD.[201.1] This highlights the importance of understanding the pharmacokinetics and pharmacodynamics of SGLT2 inhibitors in different patient populations, particularly those with varying degrees of kidney function.[202.1]
Another promising area in personalized nephrology is the use of glucagon-like peptide-1 (GLP-1) receptor agonists. These agents have shown beneficial effects on cardiorenal outcomes beyond their glucose-lowering capabilities, making them a valuable option for managing DKD.[200.1] Clinical trials have indicated that GLP-1 receptor agonists can slow the progression of diabetic CKD and reduce the need for dialysis, further emphasizing the importance of personalized treatment strategies in nephrology.[200.1]
Imaging techniques and laboratory tests are essential in the diagnosis and management of kidney diseases. The use of advanced imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) has significantly increased the incidental detection of renal lesions, which often require further diagnostic evaluation using these well-established techniques.[226.1] A study comparing the diagnostic performance of CT and MRI in detecting renal cell carcinoma (RCC) found that MRI has a higher sensitivity of 90.0% compared to CT's sensitivity of 70.0%, indicating MRI's superior ability to correctly identify RCC cases.[228.1] However, CT demonstrated greater specificity at 87.5% compared to MRI's specificity of 67.5%, suggesting that while MRI is more effective at identifying RCC, CT is more accurate in confirming the absence of the disease.[228.1] This comparative analysis underscores the importance of both imaging modalities in clinical practice for evaluating unclear renal lesions.[225.1]
In nephrology, a variety of diagnostic techniques are employed to assess kidney health and function. Common diagnostic tests include blood tests to check for infections, glucose levels, and other markers, as well as urinalysis to detect urinary tract infections or kidney problems.[207.1] Imaging studies, such as X-rays, CT scans, and MRIs, are also utilized to visualize internal structures.[207.1] The diagnostic landscape is evolving with the introduction of new biomarkers, including urinary albumin-to-creatinine ratio (UACR), kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL), which are supplanting traditional markers and providing valuable insights into kidney health.[206.1] Although these biomarkers are not yet ready for clinical use, they are significant in reviewing the role of predicting chronic kidney disease (CKD) progression and cardiovascular disease (CVD) risk in CKD patients.[235.1]
Kidney biopsies are essential diagnostic procedures, particularly indicated for new-onset nephrotic syndrome in adults, cases of significant proteinuria, and instances of unexplained renal impairment, especially when active urine sediment suggests possible crescentic glomerulonephritis.[210.1] In the field of nephrology, traditional diagnostic techniques remain crucial, as they provide vital information regarding kidney function and disease progression, which is fundamental for effective clinical management.[230.1] The reliance on these traditional indicators is underscored by the necessity of monitoring disease and the response of laboratory tests to treatment, highlighting their importance in patient management.[231.1]
Emerging technologies in nephrology diagnostics are increasingly focused on non-invasive methods that enhance the assessment of kidney health and disease progression. One notable advancement is ultrasound elastography (USE), which has gained traction for its ability to evaluate tissue elasticity in patients with chronic kidney disease (CKD) and has shown promise in both native and transplanted kidneys.[211.1] Specifically, shear wave elastography (SWE) has been explored as a potential non-invasive biomarker to differentiate between normal and abnormal renal parenchymal tissue, addressing the pressing need for reliable measures of renal fibrosis.[212.1]
Chronic kidney disease (CKD) is recognized as a major worldwide health problem, with intra-renal fibrosis serving as a final common pathway that correlates with disease severity.[213.1] The measurement of tissue stiffness can be performed non-invasively using shear wave elastography (SWE), representing a significant advancement in nephrology diagnostics.[213.1] Current biomarkers for CKD are limited by their lack of sensitivity and inability to prognosticate disease progression.[215.1] However, emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and liver-type fatty acid-binding protein (L-FABP) have been linked to kidney damage, disease severity, and progression, indicating their potential to enhance the diagnostic landscape in nephrology.[214.1] These emerging biomarkers have been examined in multiple studies and validated independently in separate cohorts, suggesting their reliability in clinical settings.[215.1]
Current biomarkers for CKD often lack sensitivity and prognostic capability, highlighting the importance of these emerging biomarkers that have been validated across multiple studies.[215.1] Additionally, advancements in laboratory techniques have improved the accuracy and efficiency of kidney function tests, which are crucial for monitoring patients with conditions such as diabetes and hypertension.[216.1] Calibration improvements in creatinine measurements have also reduced misclassification bias in estimating glomerular filtration rate (eGFR), further refining diagnostic accuracy.[217.1]
The exploration of novel biomarkers, including Cystatin C and ProEnkephalin, aims to overcome the limitations of traditional renal function assessments, thereby enhancing the precision of kidney diagnostics.[218.1] As these technologies evolve, they promise a paradigm shift in nephrology, offering real-time monitoring and greater applicability across diverse patient populations.[219.1]
Lifestyle modifications are vital in managing kidney health, especially for patients with chronic kidney disease (CKD). These modifications include medication management, dietary guidelines, and regular monitoring, forming the foundation of effective CKD care plans tailored to individual patient needs.[266.1] A comprehensive approach ensures that all critical elements of CKD management are addressed, focusing on treatment strategies that consider the underlying causes, individual characteristics, and specific needs of each patient.[266.1] For hypertensive kidney disease, a tailored approach is essential for optimizing health outcomes and effectively managing kidney health.[265.1]
A structured framework, such as a Chronic Kidney Disease Care Plan, is crucial to ensure that all aspects of CKD management are addressed for each patient.[266.1] Regular monitoring is particularly important, as CKD is characterized by irreversible kidney damage, which can be assessed through the glomerular filtration rate (GFR). The GFR is a key indicator of kidney function, reflecting the flow rate of filtered fluid through the kidneys and serving as an accurate measure of overall kidney health.[271.1]
Nephrology care emphasizes culturally sensitive practices as a best-practice approach for improving health outcomes among patients with end-stage kidney disease (ESKD).[273.1] This care is crucial for hemodialysis patients, requiring significant lifestyle changes.[273.1] Nephrology nurses play a vital role in addressing the holistic needs of these patients by establishing culturally sensitive practices that consider their social support systems, life goals, preferences, functional status, and logistical factors.[267.1] The ESKD Life-Plan promotes shared decision-making (SDM) among patients and their dialysis care teams, allowing for the development of individualized treatment plans that specifically consider the patients' current medical situations and future aspirations.[267.1] Evidence supports the effectiveness of nurse-led care in improving various aspects of health, including quality of life, sleep, pain, overall health, and depressive symptoms among CKD patients, demonstrating the positive impact of such interventions on patient outcomes.[270.1] By fostering a supportive environment, nephrology care not only aids in disease management but also encourages adherence to necessary lifestyle modifications.[270.1]
Support systems for patients with kidney disease are essential for enhancing their overall well-being and quality of life. Shared decision-making (SDM) is a critical component of these support systems, as it involves collaboration between patients and healthcare providers to arrive at informed medical decisions. Evidence indicates that SDM not only increases patients' understanding of their illness but also enhances their satisfaction with the decision-making process.[251.1] This approach allows patients to actively participate in discussions about their treatment options, risks, and benefits, thereby aligning interventions with their preferences and priorities.[253.1]
Patient-centered care in nephrology signifies a transformative approach that shifts the focus from a disease-centered model to one that prioritizes the unique experiences of patients. This model fosters active participation and collaboration between patients and healthcare professionals, allowing for a more personalized care experience.[252.1] By engaging patients in their health journey, this philosophy empowers them, making them feel valued and involved in their treatment decisions. The implementation of individualized care plans, patient education, and shared decision-making not only enhances patient engagement but also promotes improved treatment adherence and a sense of ownership over health outcomes.[254.1] Ultimately, this approach aims to transcend traditional boundaries in nephrology, striving to achieve the best possible treatment outcomes and quality of life for individuals living with kidney disease.[252.1]
Effective strategies to empower patients include minimizing the burden of chronic kidney disease (CKD)-related symptoms, which can significantly enhance patient satisfaction and health-related quality of life.[255.1] Additionally, addressing patients' psychosocial needs is crucial. Patients often express feelings of helplessness and a lack of control over their illness, which can be mitigated by ensuring they feel listened to and educated about their treatment options.[261.1] Psychosocial interventions can help reduce distressing symptoms, increase coping strategies, and foster social connectedness, although there is currently no uniform standard for these treatments.[263.1]
Education programs that involve care partners are also vital in promoting informed and activated patients with CKD. Such programs empower patients to take control of their health, ultimately improving outcomes and quality of life.[275.1] Resources like Interwell Learning, which offers a reimbursable kidney disease education series, exemplify effective patient education initiatives that combine various formats to enhance understanding and engagement.[276.1] Furthermore, organizations like the National Kidney Foundation provide a range of resources, including support networks and educational materials, to assist patients in navigating their health challenges.[277.1]
Recent advancements in nephrology have highlighted several key research trends and focus areas that are shaping the future of kidney care. One significant area of focus is the prevention and management of acute kidney injury (AKI) and chronic kidney disease (CKD), with ongoing efforts to develop innovative treatment modalities and guidelines aimed at improving patient outcomes.[289.1]
Emerging therapeutic strategies are particularly noteworthy, with the introduction of non-steroidal mineralocorticoid receptor antagonists, such as finerenone, and glucagon-like peptide-1 (GLP-1) receptor agonists, like semaglutide, showing promise in enhancing treatment for diabetic kidney disease.[290.1] Additionally, the exploration of novel diagnostic methods, including advancements in kidney imaging and renal function estimation, is expected to revolutionize the approach to kidney disease management.[293.1]
Research is also increasingly directed towards understanding the pathophysiology of kidney diseases and identifying novel therapeutic targets. This includes the investigation of kidney-specific proteins and the development of combination therapies that address residual cardiorenal risk in CKD patients.[296.1] Furthermore, the integration of personalized medicine, which tailors treatment strategies based on genetic factors and disease progression, is anticipated to significantly influence future treatment paradigms for CKD.[298.1]
The role of health policy in nephrology is increasingly vital, particularly as advocacy efforts intensify to ensure that Americans on dialysis have access to innovative treatments. A coalition of over 100 stakeholders, including patient advocacy groups, racial equity organizations, labor unions, and faith leaders, has urged Congress to pass the Kidney PATIENT Act (H.R. 5074 / S.4510) to facilitate this access.[305.1] Furthermore, organizations like the National Kidney Foundation (NKF) are at the forefront of this movement, working to eliminate preventable kidney disease and dismantle structural inequities in kidney care, dialysis, and transplantation. The NKF is committed to providing fair, equitable, and innovative treatment options, thereby enhancing the dignity of the patient experience.[306.1] Overall, the future of nephrology research and policy is characterized by a concerted effort to address disparities and improve kidney health for underserved populations.
The development of wearable artificial kidneys (WAK) represents a significant advancement in the field of nephrology, particularly for patients with end-stage renal disease. The WAK is a battery-operated device that weighs less than 5 kg and can be worn like a belt or vest, allowing for greater mobility and independence compared to traditional dialysis methods. This innovation aims to eliminate barriers associated with home hemodialysis, such as the need for electricity and water supply, thereby enhancing patient convenience and quality of life.[301.1]
Collaboration among researchers from various fields is essential to address the challenges of creating effective wearable and implantable artificial kidneys. These devices must be capable of performing vital kidney functions, including the removal of uremic toxins, maintaining electrolyte balance, and regulating fluid levels.[302.1] However, the integration of wearable artificial kidneys into everyday patient care is not without its challenges. Key issues include ensuring patient acceptance and education, as both patients and healthcare providers need to understand the functionality and benefits of these devices.[303.1]
Moreover, safety and user acceptance are critical factors that will influence the widespread adoption of wearable artificial kidneys. For successful implementation in real-world settings, it is imperative to establish safe blood access and address any potential complications that may arise during use.[304.1] As these challenges are navigated, the potential impact of wearable artificial kidneys on patient care could be transformative, offering a more flexible and less burdensome alternative to conventional renal replacement therapies.
169
medicalaffairs.travere.com
181
kidney-international.org
201
pubmed.ncbi.nlm.nih.gov
212
bmcnephrol.biomedcentral.com
225
pubmed.ncbi.nlm.nih.gov
302
pubmed.ncbi.nlm.nih.gov